NASDAQ$ERAS
Erasca Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results for the third quarter of 2022 and provided business updates.
Erasca reported positive preliminary monotherapy data for ERAS-007 and ERAS-601, signed CTCSAs with Eli Lilly and Pfizer, and a strategic R&D collaboration with MD Anderson. The company's cash, cash equivalents, and marketable securities totaled $365 million.
- Reported promising preliminary Phase 1/1b data for ERAS-007 and ERAS-601 in advanced solid tumors.
- Signed CTCSAs with Eli Lilly to supply cetuximab in combination with ERAS-601 and with Pfizer to supply palbociclib in combination with ERAS-007.
- Entered a strategic R&D collaboration with MD Anderson.
- Expects to file an IND for CNS-penetrant KRAS G12C inhibitor ERAS-3490 before year-end.
Headline financials
Revenue & EPS history
Erasca · Revenue · Quarterly
$0
Forward guidance
Erasca anticipates filing an IND for ERAS-3490 in KRAS G12C mutant NSCLC before year-end. In the first half of 2023, they expect to initiate a dose escalation trial for ERAS-007 in combination with ERAS-601 and report combination data for ERAS-007 in gastrointestinal malignancies and ERAS-601 in triple wildtype CRC.
Tailwinds
- IND filing anticipated in the second half of 2022 for ERAS-3490
- Initiation of a Phase 1b dose escalation trial for ERAS-007 in combination with ERAS-601 anticipated in the first half of 2023
- Initial Phase 1b combination data anticipated in the first half of 2023 for HERKULES-3
- Initial Phase 1b combination data in triple wildtype CRC anticipated in the first half of 2023 for FLAGSHP-1
- Initial Phase 1b combination data anticipated in 2023 for HERKULES-2
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2022
+1.1%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+1.3%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+11.0%
Q3 2022
Best reaction
-10.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | +1.0% | +32.1% | |
| Q4 2025 | -4.3% | -7.8% | +16.1% | |
| Q3 2025 | -4.2% | +7.9% | +35.8% | |
| Q1 2025 | -4.0% | -5.8% | +9.3% | |
| Q4 2024 | +6.0% | -8.2% | +25.0% | |
| Q3 2024 | -8.4% | -14.1% | -15.4% | |
| Q2 2024 | +8.3% | +16.7% | +27.9% | |
| Q1 2024 | -10.1% | -12.8% | +8.9% | |
| Q4 2023 | +4.0% | +9.1% | -4.5% | |
| Q3 2023 | -8.6% | -1.8% | -15.0% | |
| Q2 2023 | +10.6% | -3.2% | -0.8% | |
| Q1 2023 | -1.0% | -3.8% | -5.6% | |
| Q4 2022 | -2.7% | -5.8% | -3.8% | |
| Q3 2022 | +11.0% | +20.7% | -19.1% | |
| Q2 2022 | +2.5% | +4.4% | -10.8% | |
| Q1 2022 | +2.8% | +9.4% | -4.6% | |
| Q4 2021 | +9.1% | +8.1% | -9.7% | |
| Q3 2021 | +2.2% | -3.1% | -28.9% | |
| Q2 2021 | +4.8% | +8.9% | -12.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro